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Background/aim: The goal of this study was to investigate the incidence of retinopathy of prematurity (ROP) and the relationship
between risk factors and disease in premature newborns in our neonatal intensive care unit.
Materials and methods: A total of 219 premature subjects were retrospectively evaluated for retinopathy. Demographic information,
clinical data, and risk factors were reviewed.
Results: The gestational ages of the infants included in the study ranged between 25 and 36 weeks, and the birth weights ranged between
670 and 4460 g. In this study, the incidence of ROP was 20.1% (44) in preterm infants: 16 had stage 1 (36.4%), 15 had stage 2 (34.1%),
11 had stage 3 (25%), 1 had stage 4 (2.3%), 1 had stage 5 (2.3%), and 6 had plus (+) disease (7.2%). The risk factors associated with the
development of ROP included low birth weight, ventilation treatment, bronchopulmonary dysplasia, and maternal preeclampsia. The
risk factors were analyzed with logistic regression analysis. The odds ratios were 5.952 (95% confidence interval [CI]: 2.030–17.447),
20.070 (95% CI: 4.213–95.600), 5.879 (1.916–18.037), and 3.200 (95% CI: 1.002–11.535), respectively.
Conclusion: In this study, birth weight, ventilation treatment, bronchopulmonary dysplasia, and maternal preeclampsia were the most
important risk factors for the development of ROP.
Key words: Retinopathy of prematurity, birth weight, preterm infants

1. Introduction
Retinopathy of prematurity (ROP) is a proliferative
vitreoretinopathy seen in premature infants, first
described by Terry in 1942 (1); however, the etiology and
pathogenesis of ROP remain unclear. It causes vision loss
and blindness in newborns, but can be treated if detected
appropriately and timely. Many risk factors are blamed for
the development of ROP. The best known are low birth
weight and low gestational age (GA). Multiple risk factors,
including low birth weight, prematurity, oxygen therapy,
blood transfusions, apnea, postnatal steroid treatment, and
hypercapnia, contribute to the development of ROP (2,3).
Oxygen therapy also plays an important role. A strong
association exists between the severity of retinopathy and
insulin-like growth factor 1 (IGF-1) in the early period
following birth, and subsequent uncontrolled increase
has been considered a risk factor (4,5). During the first
stage of the pathogenesis of ROP, hyperoxia suppresses the
activity of the vascular endothelial growth factor (VEGF)
and alters the normal vascularization of the retina due
to vasoconstriction and vasoobliteration of the existing
* Correspondence: agebesce@fatih.edu.tr

immature vessels. In the second phase, upregulation of
VEGF and other growth factors triggered by hypoxia
induces vascular overproliferation. Thus, hypoxia and
hyperoxia are involved in the pathogenesis of ROP (6).
In more developed countries, ROP is primarily a concern
for preterm births under 28 weeks of GA and 1000 g of
weight, while severe ROP has been reported to develop
in preterm births of up to 34 weeks of GA in developing
countries (4). The incidence and risk factors of ROP have
not been identified in Turkey. In this study, we compared
the relevant literature data with the incidence of ROP and
present risk factors in premature infants in our neonatal
intensive care unit.
2. Materials and methods
Between February 2007 and January 2011, 219 premature
subjects were retrospectively evaluated for retinopathy.
Premature infants who were under 36 weeks of gestation
age and who reached the 4th week after birth were included
in the study. Premature infants who were born after 36
weeks of gestation and died in the first 4 weeks of life were
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excluded from the study. Birth weight (g); GA (weeks);
activity, pulse, grimace response, appearance, respiration
(APGAR) score; surfactant treatment; ventilator
treatment; duration of oxygen therapy; development of
intraventricular hemorrhage; presence of patent ductus
arteriosus (PDA); development of bronchopulmonary
dysplasia (BPD); frequency of blood transfusions; sepsis;
and maternal risk factors including premature rupture of
membranes, preeclampsia, and diabetes, were recorded.
2.1. Ophthalmological examination
Premature infants were first examined at 4 to 6 weeks after
birth. The pupils of the subjects were dilated 1 h before the
examination with three drops of 1% tropicamide and 2.5%
phenylephrine 14 min apart. Fundus examination was
performed with binocular indirect ophthalmoscope using
a pediatric speculum, a sclera depressor, and a +20 diopter
lens. Results were recorded according to the International
Classification of Retinopathy of Prematurity (ICROP),
which is based on the location of the disease in zones, the
circumferential extent of the disease based on the clock
hours, and the degree of vascularization stage (5). The eye
examinations of the subjects were repeated after 1–2 weeks,
depending on the findings. Subjects with stage 1 and stage
2 retinopathy were followed at our hospital, while subjects
with stage 3 retinopathy and plus disease were followed
at the Cerrahpaşa Faculty of Medicine, Department of
Ophthalmology. Laser photocoagulation was performed
on patients who had at least stage 3 disease. The other
patients were followed up until retinal vascularization was
complete.

2.2. Statistical analysis
NCSS (Number Cruncher Statistical System) 2007 and
PASS (Power Analysis and Sample Size) 2008 statistical
software (USA) were used for statistical analysis of the
results. In addition to definitive methods (mean, standard
deviation, median, frequency, ratio), the Yates continuity
correction, chi-square, Fisher’s exact chi-square, Pearson’s
chi-square, and Mann–Whitney U tests were used to
compare the data. Results were evaluated with 95%
confidence intervals (CIs) and P < 0.05 was considered
significant.
3. Results
The study was conducted on 219 premature infants born
between February 2007 and January 2011. Retinopathy
of prematurity (ROP) was found in 44 of the 219 infants
included in the study (20.1%): 16 had stage 1 (36.4%), 15
had stage 2 (34.1%), 11 had stage 3 (25%), 1 had stage 4
(2.3%), 1 had stage 5 (2.3%), and 6 had plus disease (+)
(7.2%). An overview of the general characteristics of the
subject group is shown in Table 1. The mean gestational
age of subject group was 32.81 ± 3.21 weeks, birth weight
was 2041.48 ± 733.89 g, and sex distribution was 110
(50.2%) male and 18 (49.8%) female.
Neonatal and maternal risk factors for preterm birth were
analyzed using Fisher’s exact test and the Yates continuity
correction test. The results are shown in Table 2.
Risk factors contributing to ROP, including premature
rupture of membranes (PROM), surfactant treatment,
APGAR score at the 1st minute, blood transfusions,

Table 1. Overview of general characteristics of the subject group.
Min–Max

Mean ± SD

GA

25–36

32.81 ± 3.21

BW

670–4.460

2041.48 ± 733.89

N

%

male

110

50.2

female

109

49.8

≤28

30

13.7

29–32

54

24.7

>32

135

61.6

≤1000

18

8.2

1000–1250

21

9.6

1250–1500

21

9.6

≥1500

159

72.6

Sex

GA

BW

N: number of patients (N = 219); GA: gestational age (weeks); BW: birth weight (grams).
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Table 2. Univariate analysis of factors contributing to the development of ROP.

¹Sex
²GA
²BW
²OT
²PDA
²RDS
²VT
²AS
²BPD
²Sepsis
²MP
²IVH
²BT

ROP (+)

ROP (–)

N (% )

N (% )

P

Odds ratio

95% CI

male

25 (22.7)

85 (77.3)

0.771

1.100

0.579–2.087

female

23 (21.1)

86 (78.9)

<32

38 (60.3)

25 (39.7)

0.001**

22.192

9.817–50.166

≥32

10 (6.4)

146 (93.6)

<1500

38 (63.3)

22 (36.7)

0.001**

25.736

11.244–58.905

≥1500

10 (6.3)

149 (93.7)

P

46 (26.9)

125 (73.1)

0.002**

8.464

1.975–36.282

N

2 (4.2)

46 (95.8)

P

5 (71.4)

2 (28.6)

0.006**

9.826

1.843–52.386

N

43 (20.3)

169 (79.7)

P

32 (60.4)

21 (39.6)

0.001**

14.286

6.720–30.367

N

16 (9.6)

150 (90.4)

P

41 (61.2)

26 (38.8)

0.001**

32.665

13.231–80.642

N

7 (4.6)

145 (95.4)

P

9 (28.1)

23 (71.9)

0.492

1.485

1.485–3.466

N

39 (20.9)

148 (79.1)

P

31 (75.6)

10 (24.4)

0.001**

29.359

12.293–70.117

N

17 (9.6)

161 (90.4)

P

17 (43.6)

22 (56.4)

0.001**

3.714

1.769–7.799

N

31 (17.2)

149 (82.8)

P

13 (41.9)

18 (58.1)

0.012*

2.791

1.331–6.635

N

35 (19.6)

144 (80.4)

P

9 (52.9)

8 (47.1)

0.004**

4.702

1.705–12.967

N

39 (19.3)

163 (80.7)

P

29 (74.4)

10 (25.6)

0.001**

24.575

10.380–58.175

N

19 (10.6)

161 (89.4)

BW: birth weight (grams); GA: gestational age (weeks); P: positive; N: negative;
OT: oxygen therapy; PDA: patent ductus arteriosus;
RDS: respiratory distress syndrome; VT: ventilator treatment; AS: asphyxia; BPD: bronchopulmonary dysplasia; MP: maternal
preeclampsia; IVH: intraventricular hemorrhage; BT: blood transfusion; N: number of patients.
¹Chi-square test, ²continuity correction (Yates) test, *P < 0.05, **P < 0.01.

respiratory distress syndrome (RDS), birth weight, BPD,
and maternal preeclampsia were evaluated with stepwise
logistic regression analysis. The results are shown in Table
3. The model was significant at the 10th step, and the
expressiveness coefficient was good (78.3%).

4. Discussion
The frequency of ROP was 20.1% in this study. Univariate
and multivariate logistic regression tests revealed that birth
weight, ventilation therapy, bronchopulmonary dysplasia,
and maternal preeclampsia were the most important
risk factors in the development of ROP. Different from
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Table 3. Analysis of factors contributing to the development of ROP with logistic regression.
B

SE

P

Exp (B)

95% CI

BW < 1500 g

1.784

0.549

0.001**

5.952

2.030–17.447

RDS

–1.282

0.794

0.107

0.276

0.059–1.316

VT

2.999

0.796

0.001**

20.070

4.213–95.600

BPD

1.771

0.572

0.002**

5.879

1.916–18.037

MP

1.163

0.654

0.045*

3.200

1.002–11.535

BW: birth weight (grams); RDS: respiratory distress syndrome; VT: ventilator treatment; BPD: bronchopulmonary dysplasia; MP:
maternal preeclampsia. *P < 0.05, **P < 0.01.

other previously published studies, we identified that the
duration of ventilation treatment did not affect the severity
of ROP. Recently, the survival rates of neonates with very
low birth weight and GA have rapidly increased parallel
to the advances in assisted reproductive technologies
and neonatology. As a result, there has been an increase
in the incidence of ROP over the years (6). Retinopathy
is one of the most important problems in risky preterm
births and can lead to visual impairments and potentially
to blindness. However, ROP can be prevented with
appropriate and early detection and treatment. Therefore,
knowing the causes and risk factors of ROP is crucial for
preventing the disease.
A wide range of ROP incidence (23%–56.2%) has
been reported in Turkey (7–9). The frequency was slightly
lower in our study. In this study, the frequency of ROP
was 9.1% in infants who weighed more than 2000 g, and
13.6% in infants over 32 weeks of GA. We detected 4
patients with stage 3 ROP whose birth weeks were over 33
weeks, and all required surgical treatment. Akman et al.
also detected 11 infants with ROP who required surgical
treatment and whose GA was between 32 and 34 weeks
(10). Another study conducted in Turkey demonstrated
that the frequency of ROP was 56% in infants with 32–35
weeks of GA. Similar findings were shown in studies from
Saudi Arabia, Vietnam, India, and China, and in Turkey,
with recommendations to include more mature infants in
screening programs to avoid missing cases (7,11,12).
In this study, the risk of ROP development was 32.7
times higher in infants who received ventilation treatment
using univariate testing (Table 2). In addition, the odds
ratio was 20.1 in logistic regression analysis. Therefore,
we found that mechanical ventilation treatment was the
most important risk factor in ROP development. Various
studies have reported that ventilator treatment increases
the development of ROP (13–15). However, the effect
of ventilator treatment is markedly larger in our study.
Mechanic ventilation delivers oxygen to the lungs with
positive pressure, and a longer exposure to high oxygen
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pressure may contribute to ROP development. Recently,
Giannantonio et al. published findings on ROP risk factors
and noted that prolonged mechanical ventilation was also
associated with ROP requiring treatment (14). Fortes Fillo
et al. found that mechanical ventilation was a significant
risk factor only for the development of ROP in infants
with a GA of 32 weeks or greater (15). The researchers
concluded that although infants with a lower GA are
challenged with consequences of general immaturity,
larger infants with higher GA tend to be sicker with more
comorbidity. We found that the number of infants under
32 weeks (84) was much lower than the number of infants
over 32 weeks (135), and ventilation treatment was the
most important factor contributing to the development of
ROP. These findings supported the results of their study.
In our study, the risk of developing ROP was 29.4 times
higher in infants with bronchopulmonary dysplasia using
univariate testing (Table 2). In addition, the odds ratio
for the presence of bronchopulmonary dysplasia was 5.9
in logistic regression analysis (Table 3). Holmström et al.
found that the presence of bronchopulmonary dysplasia
was the most powerful risk factor in the development of
ROP (16). Giapros et al. showed the synergistic effect of low
GA and chronic pulmonary disease on the development of
ROP (17). In our study, patients with bronchopulmonary
dysplasia had a birth weight of less than 1000 g, received
postnatal steroids, and were under long-term ventilator
and oxygen therapy. Therefore, other risk factors may
have synergistic effects. Zamorano Jimenez et al. observed
that postnatal steroid treatment was a risk factor for the
development of ROP (18). Similarly, Shah et al. showed
that chronic pulmonary disease was a risk factor for ROP
that required surgery (13).
Low birth weight and short GA have been confirmed
as the key risk factors for the development of ROP (16,19).
Our study and other studies conducted in Turkey have
demonstrated that birth weight was more important than
GA as a risk factor in the development of ROP (20,21)
(Figures 1 and 2).
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100
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Figure 1. Distribution of ROP according to birth weight.

Figure 2. Distribution of ROP according to GA.

Several studies conducted in Turkey and throughout
the world revealed that maternal preeclampsia
played an important role in the development of ROP
(13,16,18,22,23). Similarly, we found that the odds ratio
for maternal preeclampsia was 3.2 using logistic regression
tests (Table 3). In addition, the presence of preeclampsia in
mothers of 4 infants with ≥2000 g birth weight and ROP
(+) is remarkable. Although the exact mechanism of ROP
in infants born to preeclamptic mothers is not known,
retinal hypoxia, altered maternal angiogenic factors,
inflammation, and oxidative stress might contribute to this
multifactorial morbidity.
Other risk factors that contribute to the development
of ROP include sepsis, RDS, hypercapnia, acidosis,
anemia, intraventricular hemorrhage, blood transfusions,
multiple pregnancy, and neonate APGAR score. However,
the question of which factor independently causes
retinopathy is unanswered (20,23,24 ). Multiple risk
factors may be present in the same infant. In our study,
we found that blood transfusion, sepsis, PROM, PDA, IVF,
and an APGAR score of 7 or lower contributed to the risk,
while intraventricular hemorrhage, maternal diabetes, and
neonatal convulsions did not.
Although ROP is predominantly reported in infants
below 28 weeks of GA and 1000 g of birth weight in
developed countries, in developing countries severe ROP
may develop in up to 34-week preterm babies (25,26). In
addition, the presence of severe ROP that required surgery
in 4 subjects with birth weights higher than 1500 g and GA

older than 33 weeks further showed the need for follow-up
for retinopathy in all preterm infants.
According to the last declaration of the American
Academy of Ophthalmology, the American Academy of
Pediatrics, and the American Association for Pediatric
Ophthalmology and Strabismus, all babies below 1500 g
of birth weight or 32 weeks of GA must be screened for
ROP; moreover, infants with birth weights of 1500–2000
g or with more than 32 weeks of GA who have some
risk factors for ROP formation should be screened (27).
Although individual guidelines exist for each neonatal
intensive care unit, as in most developed countries, there
are no evidence-based national screening guidelines in
Turkey. The increasing number of studies conducted in
Turkey has shown that national guidelines are needed, and
older infants should undergo screening (28).
In conclusion, we found that low birth weight
(specifically below 1000 g), bronchopulmonary dysplasia,
maternal preeclampsia, and ventilation treatment were
the most common risk factors for the development of
ROP. Our study mainly consisted of infants who were
over 32 weeks of GA and 1500 g of weight. Thus, we shed
light on the risk factors for developing ROP. To prevent
irreversible visual loss, the population at risk should be
better identified, risk factors should be recognized, and
appropriate screening criteria should be adopted. Until
those criteria are established, caution should be taken,
and wider screening criteria than those used in developed
countries should be applied.
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